At the news
? BULLISHIMPACT 6/10 6-K filed Jul 17, 2026 at 06:02 ET
Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indications, making it the first anticancer treatment administered via an on-body injector. The approval, supported by the Phase 3 IRAKLIA study showing non-inferior efficacy with shorter administration time and fewer infusion reactions, strengthens Sarclisa's competitive positioning and may drive adoption through improved patient convenience.
- FDA approved subcutaneous Sarclisa Escena across all existing IV indications for multiple myeloma
- First anticancer treatment to be administered via an on-body injector (CirCLIQ OBI)
- IRAKLIA Phase 3 study demonstrated non-inferior ORR (71.1% SC vs 70.5% IV) with significantly fewer systemic administration reactions (1.5% vs 25%)
- Sarclisa has been prescribed to over 70,000 patients worldwide and is approved in nearly 60 countries
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access